Table 1.
Characteristics of patients with ESCC in development and validation cohorts.
|
Development cohort (n = 173) |
Internal validation cohort (n = 148) | External validation cohort (n = 90) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic |
LNM (–) (n = 93) |
LNM (+) (n = 80) |
p |
LNM (–) (n = 77) |
LNM (+) (n = 71) |
p |
LNM (–) (n = 50) |
LNM (+) (n = 40) |
p |
| Age (mean ± SD, year) | 57.83 ± 8.51 | 56.74 ± 8.09 | 0.389 | 58.91 ± 8.09 | 57.63 ± 8.15 | 0.342 | 59.86 ± 8.48 | 58.65 ± 9.58 | 0.533 |
| Sex, No. (%) | 0.445 | 0.695 | 0.507 | ||||||
| Male | 70 (75.27) | 65 (81.25) | 61 (79.22) | 59 (83.10) | 40 (80.00) | 35 (87.50) | |||
| Female | 23 (24.73) | 15 (18.75) | 16 (20.78) | 12 (16.90) | 10 (20.00) | 5 (12.50) | |||
| Tumor location (%) | 0.135 | 0.082 | 0.362 | ||||||
| Up | 11 (11.83) | 7 (8.75) | 14 (18.18) | 5 (7.04) | 8 (16.00) | 3 (7.50) | |||
| Medium | 45 (48.39) | 29 (36.25) | 32 (41.56) | 28 (39.44) | 25 (50.00) | 19 (47.50) | |||
| Low | 37 (39.78) | 44 (55.0) | 31 (40.26) | 38 (53.52) | 17 (34.00) | 18 (45.00) | |||
| Histologic grade (%) | 0.438 | 0.130 | 0.945 | ||||||
| Well differentiated | 18 (19.36) | 10 (12.5) | 12 (15.58) | 11 (15.49) | 11 (22.00) | 8 (20.00) | |||
| Moderately differentiated | 48 (51.61) | 47 (58.75) | 48 (62.34) | 34 (47.89) | 27 (54.00) | 23 (57.50) | |||
| Poorly differentiated | 27 (29.03) | 23 (28.75) | 17 (20.08) | 26 (36.62) | 12 (24.00) | 9 (22.50) | |||
| CT-reported LN status (%) | <0.001 | <0.001 | 0.007 | ||||||
| LN-negative | 61 (65.59) | 29 (36.25) | 52 (67.53) | 24 (33.80) | 33 (66.00) | 14 (35.00) | |||
| LN-positive | 32 (34.41) | 51 (36.75) | 25 (32.47) | 47 (66.20) | 17 (34.00) | 26 (65.00) | |||
LNM, lymph node metastasis; LN, lymph node; CT, computed tomography.